Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant
May 6, 2025Mergers and Acquisitions (OTC & VMS), Clayton, Clayton Dubilier & Rice (CD&R), Corporate, M&A, Opella, Sanofi, agreement
Sanofi and Clayton, Dubilier & Rice (CD&R) have officially closed the sale of a controlling 50% stake in Opella, Sanofi’s …
Genmab to submit FDA application for lymphoma therapy
May 2, 2025Research and Development AbbVie, Biologics License Application, FDA, Genmab, Oncology, epcoritamab, lymphoma, therapeutics
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) …
Ambitious plans for leading cancer research centre announced
May 2, 2025Market & Product Development, Medical Communications, Research and Development Aviva Capital Partners (ACP), Institute of Cancer Research (ICR), London, London Cancer Hub, Oncology, Royal Marsden NHS Foundation Trust, Socius
Aviva Capital Partners (ACP), an infrastructure and real estate investor, and Socius, a mixed-use developer, have unveiled plans for a …
Clinigen announces executive appointments to drive growth and investor value
May 1, 2025Business Services, Pharmaceutical Consultancy Services Clinigen, Keith Bryne, Nihad Hasagic, Pharma services, Pharmacy, appointment
Clinigen, the global pharmaceutical services group, has announced key leadership changes to accelerate its growth and strengthen its position in …
Tozaro appoints Jason Slingsby as CEO to lead commercial strategy in cell and gene therapy sector
May 1, 2025Manufacturing Services, Manufacturing and Production, Research and Development CEO, CGT, Jason Slingsby, Michele Pedrocchi, Pharmacy, Tozaro, manufacturing
Tozaro, a technology provider specialising in cell and gene therapy (CGT) manufacturing, has appointed Jason Slingsby (pictured left) as its …
Deadly cancers are being financially left behind, new research claims
May 1, 2025Research and Development Jude, Oncology, UK, bladder cancer, cancer research, charitable funding
New research has revealed that some of the UK’s most deadly and prevalent cancers receive the least amount of charitable …
Neogap chosen for Innovate Nordics 2025 Acceleration Programme
May 1, 2025Research and Development Innovate Nordics, Neogap Therapeutics, Oncology, biotech, funding programme, immunotherapy
Swedish biotech company Neogap Therapeutics has been chosen to join Innovate Nordics’ 2025 acceleration programme, a prestigious initiative designed to …
Cervical cancer experts campaign to increase screening rates and save lives
April 30, 2025Research and Development NHS, NHS England, Oncology, campaign, cervical cancer, screening
A coalition of experts fighting to end cervical cancer, referred to as the UK Consensus Group of the Advancing Cervical …
Novo Nordisk Foundation expands ambitious Challenge Programme internationallyÂ
April 30, 2025Research and Development Challenge Programme, Denmark, Novo Nordisk, Pharmacy, international
The Novo Nordisk Foundation Challenge Programme, a leading open competition grant programme, invites researchers outside of Denmark to participate and …
Gifthealth appoints Chip Parkinson as CEO to lead next phase of growth
April 29, 2025Business Services, Pharmaceutical Consultancy Services CEO, Gifthealth, Pharmacy, pharmacy care
Gifthealth, a technology-driven pharmacy care company, has appointed Chip Parkinson as its new chief executive officer. The move marks a …
Ryan Smith appointed as global head of sales at Astoriom
April 29, 2025Logistics & Distribution, Research and Development Astoriom, Pharmacy, appointment, sample storage solutions
Global R&D sample stability and biorepository storage company, Astoriom, has announced the appointment of Ryan Smith as global head of …
EU approval granted for rare kidney disease treatment
April 29, 2025Market Access, Research and Development, Sales and Marketing CSL Vifor, EU, Nephrology, Travere Therapeutics, kidney disease, nephrology
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ therapy for primary IgA nephropathy …
Study finds new test could better predict risk of heart disease
April 28, 2025Research and Development Cardiology, Chalmers University of Technologyu, Harvard, cholesterol tests, cvd
A study by Harvard University, US, and Chalmers University of Technology, Sweden, has found that measuring a lipoprotein marker combination …
Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia
April 28, 2025Pharmacy sales & educational programmes, Sales and Marketing Haematology, Sanofi, World Federation of Hemophilia, bleeding disorder, sobi
Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World Federation of Hemophilia (WFH) Humanitarian …
McDavid Stilwell appointed as CFO of CPTx
April 28, 2025Research and Development CPTx, Immunology, Oncology, appointment, cfo, therapeutics
CPTx, a German biotech company focused on single-stranded DNA therapeutics, has announced the appointment of McDavid Stilwell as chief financial …
Pharma supply chain event LogiPharma celebrates another successful year
April 28, 2025Industry Associations, Medical Communications Cold Chain Technologies, DB Schenker, LogiPharma, Pharmacy, PluumoPlus, supply chain event, supply chain professionals
In Lyon, France, over 2,200 life sciences supply chain professionals gathered for LogiPharma 2025, a leading conference dedicated to supply …
Successful clinical outcomes for drug treating rare stroke condition
April 25, 2025Research and Development Bioxodes, Neurology, clinical trial, stroke
Flemish biopharma company, Bioxodes, has announced promising results from the BIRCH phase 2a clinical trial of BIOX-101 to treat intracerebral …
Mosaic Therapeutics in-licenses clinical oncology programmes from Astex Pharma
April 25, 2025Clinical Trial Services, Industry Associations, Mergers and Acquisitions, Research and Development Astex pharmaceuticals, Mosaic Therapeutics, Oncology, clinical trial
Two clinical-stage oncology programmes from Astex Pharmaceuticals have been announced by Mosaic Therapeutics, allowing it to develop targeted oncology drug …
Philippe Masset appointed to Vect-Horus board of directors
April 25, 2025Research and Development Oncology, Vect-Horus, appointment, board of directors, imaging agents
Vect-Horus has announced the appointment of Philippe Masset to the company’s board of directors. This contributes to a series of …
Mursla Bio’s platform for surveillance of liver cancer receives FDA approval
April 24, 2025Industry Associations, Research and Development BDD, FDA, Mursla Bio, Oncology, hepatocellular carcinoma (HCC), liver disease
The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to EvoLiver, Mursla Bio’s surveillance platform for …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
